drugset / Trial / NCT00475696

Urge Incontinence Bladder Overactivity Study

NCT00475696

Phase 2 Completed 300 enrolled Eli Lilly and Company
Non-randomizedSingle-groupOpen-labelTreatment

Summary

Examine the efficacy and safety of duloxetine in subjects with symptoms of bladder overactivity due to pure detrusor instability or sensory urgency. Subjects in study will be permitted to escalate or de-escalate between 80 mg/day and 120 mg/day in consultation with the investigator and based on their adverse events.

Timeline

Start
2002-11
Primary completion
Completion
2005-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Duloxetine Small molecule 80 mg
Subject Duloxetine Small molecule 120 mg

Indications

No indication recorded.